I
ISA Pharmaceuticals
Biotech & Life Sciences · Leiden, Netherlands · Founded 2004
Developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections MoreLess
ISA Pharmaceuticals focuses on developing targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections. The company operates in the biotechnology sector, primarily serving patients and healthcare providers. ISA Pharmaceuticals' business model revolves around the research, development, and commercialization of immunotherapy treatments. Revenue is generated through the sale of these treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies. The company is actively involved in clinical trials, such as the Phase II combination trial of its lead immunotherapy ISA101b. ISA Pharmaceuticals also adapts to emerging health crises, as evidenced by its development of ISA106 SLP therapeutic for COVID-19. Keywords: immunotherapeutics, cancer treatment, virus infections, biotechnology, clinical trials, ISA101b, ISA106, COVID-19, healthcare, rational design.
Company overview
ISA Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Closed
- Founded
- 2004
- Headquarters
- Leiden, Netherlands
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 0.0
Valuation & funding
ISA Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2021 | $29M | $114M | Invest-NL · Regeneron Pharmaceuticals | — |
| DEBT✓Debt | Oct 2019 | $22M | — | European Investment Bank | — |
| EARLY VC✓Equity / VC | Jan 2013 | $8.8M | $35M | Undisclosed | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 5 |
| 2025 | 5 |
| 2024 | 9 |
| 2023 | 50 |
| 2022 | 44 |
| 2021 | 36 |
| 2020 | 28 |
Growth signals
ISA Pharmaceuticals website traffic
Latest recorded traffic for ISA Pharmaceuticals is 610 monthly website visits, up 5.2% over the last three months. ISA Pharmaceuticals's team grew 0% over the past year.
Comparisons
ISA Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
ISA Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Investors
5 investors on ISA Pharmaceuticals's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where ISA Pharmaceuticals has talent and traffic
In the news
Latest news about ISA Pharmaceuticals
Recent press, funding announcements, and product moves mentioning ISA Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about ISA Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about ISA Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ISA Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.